Henry Ford Hospital

Running trials

• Not yet recruiting

  Hummingbird ICE Study

  NCT07552272· Philips Clinical & Medical Affairs Global· Source

• Recruiting

  Deployment of a Novel National Institute of Neurological Disorders and Stroke Clinical, Biomarker, Imaging, and Modifiers (CBI-M) Classification Framework for Emergency Department Patients With Glasgow Coma Scale 15 Traumatic Brain Injury (PIONEER-Prognosis)

  NCT07858266· University of Michigan· Source

• Recruiting

  Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

  NCT06948552· Phase 2· Henry Ford Health System· Source

• Recruiting

  A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

  NCT07625215· Phase 2· Bayer· Source

• Recruiting

  A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

  NCT07214376· Pulnovo Medical, Inc.· Source

• Recruiting

  Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

  NCT07511361· Phase 2· Kardigan, Inc.· Source

• Enrolling by invitation

  Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection

  NCT07198945· Indiana University· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Enrolling by invitation

  Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

  NCT06773936· Phase 2· SWOG Cancer Research Network· Source

• Recruiting

  Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

  NCT07200830· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Indiana University· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· NRG Oncology· Source

• Recruiting

  Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD

  NCT07051707· Nuvaira, Inc.· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Michigan Initial Experience Using Tigertriever for Thrombectomy

  NCT07363525· Henry Ford Health System· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

  NCT07155174· Phase 2· AbbVie· Source

• Recruiting

  The RADIANCE CED Study

  NCT07231757· ReCor Medical, Inc.· Source

• Recruiting

  Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  NCT07001748· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Vascular Trial Associated Registry Pilot

  NCT07076082· Phase 4· Corewell Health West· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

  NCT07097142· Phase 3· NRG Oncology· Source

• Recruiting

  Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  NCT07190222· Phase 3· Sanofi· Source

• Recruiting

  Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

  NCT06689839· EnCompass Technologies, Inc.· Source

• Recruiting

  Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

  NCT06955169· Phase 2· RTOG Foundation, Inc.· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Boston Scientific Corporation· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

• Recruiting

  Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

  NCT06779630· Teleflex· Source

• Recruiting

  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979362· Phase 2· Novo Nordisk A/S· Source

• Recruiting

  Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

  NCT07001800· Phase 2/3· Kardigan, Inc.· Source

• Recruiting

  The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

  NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

  NCT06848088· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

  NCT05066217· Phase 3· Epygenix· Source

• Recruiting

  A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  NCT06615050· Phase 3· Incyte Corporation· Source

• Recruiting

  Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

  NCT06869785· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  NCT06772623· Phase 1/2· AbbVie· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Medtronic Cardiovascular· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

  NCT06799000· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

Showing 50 of 295.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer10 recruiting
• Prostate cancer9 recruiting
• Colorectal cancer8 recruiting
• Aortic stenosis7 recruiting
• Bladder cancer6 recruiting
• Coronary artery disease6 recruiting
• Heart failure6 recruiting
• High blood pressure6 recruiting
• Gastric and oesophageal cancer5 recruiting
• Head and neck cancer5 recruiting
• Metastatic breast cancer4 recruiting
• Neuroendocrine tumours4 recruiting
• Pancreatic cancer4 recruiting
• Stroke4 recruiting
• Childhood cancers3 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• COPD3 recruiting
• Kidney cancer3 recruiting
• Ovarian cancer3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Follicular lymphoma2 recruiting
• Glioblastoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Meningioma2 recruiting
• Multiple myeloma2 recruiting
• Peripheral artery disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dilated cardiomyopathy1 recruiting
• Down syndrome1 recruiting
• HIV1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Melanoma1 recruiting
• Myasthenia gravis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Sarcoma1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Duke University· Source

• Withdrawn

  Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

  NCT04684212· Brian O'Neill MD· Source

• Completed

  RECOVER-AUTONOMIC Platform Protocol

  NCT06305780· Phase 2· Kanecia Obie Zimmerman· Source

• Recruiting

  A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

  NCT06095505· Phase 2· Puma Biotechnology, Inc.· Source

• Recruiting

  Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

  NCT06136624· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

  NCT06017609· Phase 2· Shionogi Inc.· Source

• Terminated

  IMM60 and Pembrolizumab in Melanoma and NSCLC

  NCT05709821· Phase 1/2· iOx Therapeutics· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06130566· Phase 3· Sanofi· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  ADJUnct Semaglutide Treatment in Type 1 Diabetes

  NCT05537233· Phase 2· Viral N. Shah· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

  NCT05336409· Phase 1· Century Therapeutics, Inc.· Source

• Completed

  A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

  NCT05619744· Phase 1· Hoffmann-La Roche· Source

• Completed

  HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

  NCT05623189· Phase 2· HighTide Therapeutics (Hong Kong) Limited· Source

• Withdrawn

  A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

  NCT05572463· Phase 1/2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Terminated

  SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

  NCT05375084· Phase 1· Navire Pharma Inc., a BridgeBio company· Source

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Recruiting

  Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  NCT04895436· Phase 2· AbbVie· Source

• Completed

  A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

  NCT05388474· Theratechnologies· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Terminated

  Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  NCT04982224· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Pfizer· Source

• Recruiting

  JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

  NCT05064540· Endologix· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

  NCT04840914· Phase 1· Eli Lilly and Company· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source

• Completed

  The Support, Educate, Empower (SEE) Program

  NCT04735653· University of Michigan· Source

• Completed

  Pressure-Volume Loop During High-Risk PCI

  NCT04681313· Henry Ford Health System· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

  NCT04644237· Phase 2· Daiichi Sankyo· Source

• Terminated

  PF-07284892 in Participants With Advanced Solid Tumors

  NCT04800822· Phase 1· Pfizer· Source

• Recruiting

  A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

  NCT04710576· Phase 2· Syndax Pharmaceuticals· Source

• Recruiting

  Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

  NCT04683250· Phase 1/2· Taiho Pharmaceutical Co., Ltd.· Source

• Terminated

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Phase 1/2· Pfizer· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

  NCT04242199· Phase 1· Incyte Corporation· Source

• Terminated

  Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

  NCT04394624· Phase 2· Sanofi· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

  NCT04300556· Phase 1/2· Eisai Inc.· Source

• Completed

  Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

  NCT04505436· Phase 2· Hanmi Pharmaceutical Company Limited· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Oxurion· Source

• Completed

  A Study of DF6002 Alone and in Combination With Nivolumab

  NCT04423029· Phase 1· Dragonfly Therapeutics· Source

Showing 50 of 115.

Conditions

Diseases this institution publishes on or runs trials for.

• Hidradenitis suppurativa21 works · 1 trial
• Vitiligo20 works · 0 trials
• Atopic dermatitis (eczema)17 works · 4 trials
• Aortic stenosis15 works · 15 trials
• Hepatitis C11 works · 1 trial
• Primary biliary cholangitis8 works · 1 trial
• Essential tremor4 works · 0 trials
• Narcolepsy3 works · 0 trials